RTP Mobile Logo
Oncology Grand Rounds Series: Part 2 — Hodgkin and Non-Hodgkin Lymphomas
Released June 2019

Video proceedings from the second in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Christopher R Flowers, Ms Amy Goodrich, Dr Patrick B Johnston and Ms Robin Klebig. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lymphomas.

    OVERVIEW OF ACTIVITY
    Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. The biologic heterogeneity among the lymphomas gives rise to marked differences with respect to epidemiology, pathologic characteristics, clinical presentation and optimal management. The two major types are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). In the United States, an estimated 82,310 new cases of HL and NHL will be diagnosed in 2019, with 20,970 deaths attributed to these diseases. Although HL can often be cured, the prognosis for NHL depends on the specific subtype. The past several years represent a period of substantial progress in the development and evaluation of novel agents across many lymphoma subtypes. Also, mature clinical trial results have illustrated the efficacy of several new investigational therapies, a number of which have entered the clinic, thereby altering the therapeutic algorithms for HL and various NHL subtypes. The extensive list of available therapeutic options for patients with lymphoma poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    Although many of the educational needs related to the care of patients with lymphoma are relevant specifically to the practicing medical oncologists and hematologists directly responsible for therapeutic decision-making, prospective and retrospective patient-level research has shown that oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and in the preservation of the physical and psychosocial well-being of patients. These video proceedings from the second part of a 6-part integrated CNE curriculum originally held at the 2019 ONS Annual Congress feature discussions with leading HL/NHL investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for patients with HL, follicular lymphoma (FL), mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lymphomas.

    LEARNING OBJECTIVES

    • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory (R/R) FL, MCL, DLBCL and HL, and use this information to enhance decision-making for patients diagnosed with these diseases.
    • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of existing and recently approved systemic therapies for FL, MCL, DLBCL and HL to support quality of life and continuation of therapy.
    • Recall the biologic rationale for, available research data with and ongoing research efforts evaluating the use of chemotherapy-free combinations in the management of newly diagnosed and progressive FL and MCL, and use this information to guide protocol and off-protocol care for these patients.
    • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with R/R DLBCL and other lymphomas for whom this approach may be appropriate.
    • Describe available and emerging data with other investigational agents and immunotherapeutic strategies currently under evaluation for FL, MCL, DLBCL and HL, and, where applicable, refer eligible patients for trial participation.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CREDIT DESIGNATION STATEMENTS
    This educational activity for 2.1 contact hours is provided by RTP during the period of June 2019 through June 2020.

    This activity is awarded 2.1 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit ResearchToPractice.com/ONS2019/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSLymphomas2019/CNE.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Christopher R Flowers, MD, MS
    Professor, Hematology and Medical Oncology
    Director, Emory Lymphoma Program
    Scientific Director, Winship Research Informatics
    Winship Cancer Institute
    Atlanta, Georgia

    Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, Denovo Biopharma, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, OptumRx Inc, Pharmacyclics LLC, an AbbVie Company, Spectrum Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Burroughs Wellcome Fund, Celgene Corporation, Eastern Cooperative Oncology Group, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, National Cancer Institute, Roche Laboratories Inc, Takeda Oncology, TG Therapeutics Inc, V Foundation for Cancer Research; Uncompensated Consulting: Celgene Corporation, Genentech, Roche Laboratories Inc.

    Amy Goodrich, CRNP
    Nurse Practitioner
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine
    Baltimore, Maryland

    Advisory Committee: Gilead Sciences Inc, Mylan Pharmaceuticals Inc, Sandoz Inc, a Novartis Division.

    Patrick B Johnston, MD, PhD
    Consultant in Hematology and Blood and Marrow Transplant
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    Robin Klebig, APRN, CNP, AOCNP
    Nurse Practitioner
    Division of Hematology, Lymphoma Group
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RTP CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2019
    Expiration date: June 2020

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):